Cargando…

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice

Therapeutic drug monitoring (TDM) is the measurement of drug and antidrug antibody concentrations in individuals to guide treatment decisions. In patients with Crohn disease (CD), TDM, used either reactively or proactively, is emerging as a valuable tool for optimization of tumor necrosis factor (TN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vande Casteele, Niels, Feagan, Brian G, Wolf, Douglas C, Pop, Anca, Yassine, Mohamed, Horst, Sara N, Ritter, Timothy E, Sandborn, William J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Review Article - Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314098/ https://www.ncbi.nlm.nih.gov/pubmed/33051647 http://dx.doi.org/10.1093/ibd/izaa265

Ejemplares similares

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017)

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study
por: Vande Casteele, Niels, et al.
Publicado: (2020)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
por: Papamichael, Konstantinos, et al.
Publicado: (2022)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn’s Disease
por: Verdon, Christine, et al.
Publicado: (2020)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
por: Holmer, Ariela K., et al.
Publicado: (2020)

Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
por: Singh, Siddharth, et al.
Publicado: (2018)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
por: Mosli, Mahmoud H., et al.
Publicado: (2015)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial
por: Panaccione, Remo, et al.
Publicado: (2015)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
por: Paul, Stéphane, et al.
Publicado: (2020)

Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: Lefevre, Pavine L C, et al.
Publicado: (2020)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021)

Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
por: Hemperly, Amy, et al.
Publicado: (2021)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody
por: Pichler, Judith, et al.
Publicado: (2020)

Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis
por: Linggi, Bryan, et al.
Publicado: (2021)

Histochemistry, Theoretical and Applied
por: Velardo, Joseph Thomas
Publicado: (1960)

Applied biopharmaceutics & pharmacokinetics
por: Shargel, Leon, 1941-
Publicado: (1999)

Applied biopharmaceutics and pharmacokinetics
por: Shargel, Leon, 1941-
Publicado: (1993)

Frontiers in Theoretical and Applied Physics
Publicado: (2017)

Advances in theoretical and applied statistics
por: Torelli, Nicola, et al.
Publicado: (2013)

Topics in theoretical and applied statistics
por: Alleva, Giorgio, et al.
Publicado: (2016)

Studies in Theoretical and Applied Statistics
por: Perna, Cira, et al.
Publicado: (2018)

Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease
por: Arulanandan, Ahilan, et al.
Publicado: (2016)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
por: Mantzaris, Gerassimos J., et al.
Publicado: (2015)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Second Korean guidelines for the management of Crohn's disease
por: Park, Jae Jun, et al.
Publicado: (2017)

Applied group-theoretic and matrix methods
por: Higman, Bryan
Publicado: (1955)

Cannot write session to /tmp/vufind_sessions/sess_crj767jnpkeaj09tibe73fci0d